Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$6.1B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation operates in the biotechnology sector, focusing on developing innovative therapies for cancer and other serious diseases. With a market cap of $6 billion, the company's advancements in cell therapy are particularly relevant as the healthcare industry increasingly seeks targeted treatments.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1-2024, Legend Biotech reported an EPS of -$0.16, outperforming expectations by 44.44%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent EPS surprise. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Legend Biotech continues to beat EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2-2024?

Revenue is crucial for assessing the company's growth trajectory and market demand for its products.

Will management provide guidance for future quarters?

Guidance can significantly influence investor sentiment and expectations regarding the company's performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Legend Biotech's therapies to gain traction, especially given the recent EPS surprise.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger underlying performance than anticipated.

Options pricing suggests heightened volatility, indicating that traders expect significant movement based on the earnings report.

Key Risk

If the revenue figure exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized as it could set the tone for future growth and investor confidence.

Bull Confirmed If

A revenue figure that exceeds analyst expectations would confirm strong market demand for Legend's therapies.

Bear Confirmed If

A revenue figure that falls short of expectations could raise concerns about the company's growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 6.91% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the commercialization of new therapies.
2Management's commentary on market demand and competitive landscape.
3Details on ongoing clinical trials and their expected timelines.
4Insights into cost management and operational efficiency.
5Any new partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1-2024, Legend Biotech reported an EPS of -$0.16, outperforming expectations by 44.44%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent EPS surprise. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Legend Biotech continues to beat EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2-2024?

Revenue is crucial for assessing the company's growth trajectory and market demand for its products.

Will management provide guidance for future quarters?

Guidance can significantly influence investor sentiment and expectations regarding the company's performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Legend Biotech's therapies to gain traction, especially given the recent EPS surprise.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger underlying performance than anticipated.

Options pricing suggests heightened volatility, indicating that traders expect significant movement based on the earnings report.

Key Risk

If the revenue figure exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized as it could set the tone for future growth and investor confidence.

Bull Confirmed If

A revenue figure that exceeds analyst expectations would confirm strong market demand for Legend's therapies.

Bear Confirmed If

A revenue figure that falls short of expectations could raise concerns about the company's growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 6.91% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the commercialization of new therapies.
2Management's commentary on market demand and competitive landscape.
3Details on ongoing clinical trials and their expected timelines.
4Insights into cost management and operational efficiency.
5Any new partnerships or collaborations that could enhance growth.